Q-omics provides the consensus-scored RALY profile across patient tissues and cancer cell-line models. RALY expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RALY is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RALY protein abundance shows 25,043 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where RALY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RALY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RALY survival associations across molecular data types. RALY RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RALY RNA expression–survival associations across cancer types. High RALY expression shows unfavorable associations in ACC, LIHC, MESO, KICH, LGG and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RALY RNA expression.
This table summarizes RALY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RALY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RALY shows higher tumor expression in HNSC, KIRC, COAD, LIHC, KIRP and STAD. The HNSC box plot shows higher RALY RNA expression in tumor versus normal tissue (log2 FC = +1.151, t-test p < 0.001).
This table shows molecular features associated with RALY in patient tissues and cancer cell lines. In patient samples, RALY shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RALY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
